Please try another search
© Reuters. FILE PHOTO: Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City, U.S., August 4, 2017. REUTERS/Carlo Allegri
By Diane Bartz and Jonathan Stempel
WASHINGTON (Reuters) -A U.S. judge on Friday barred Martin Shkreli from the pharmaceutical industry for life and ordered him to pay $64.6 million after he famously raised the price of the drug Daraprim and fought to block generic competitors.
U.S. District Judge Denise Cote in Manhattan ruled after a trial where the U.S. Federal Trade Commission and seven states had accused Shkreli, the founder of Vyera Pharmaceuticals, of using illegal tactics to keep Daraprim rivals out of the market.
Shkreli drew notoriety in 2015 after hiking Daraprim's price overnight to $750 per tablet from $17.50. The drug treats toxoplasmosis, a parasitic infection that threatens people with weakened immune systems.
In a 130-page decision, Cote faulted Shkreli for creating two companies, Vyera and Retrophin (NASDAQ:TVTX) Inc, designed to monopolize drugs so he could profit "on the backs" of patients, doctors and distributors.
She said the Daraprim scheme was "particularly heartless and coercive," and a lifetime industry ban was needed because of the "real danger" that Shkreli could become a repeat offender.
"Shkreli's anticompetitive conduct at the expense of the public health was flagrant and reckless," the judge wrote. "He is unrepentant. Barring him from the opportunity to repeat that conduct is nothing if not in the interest of justice."
After the ruling, FTC Chair Lina Khan tweeted the decision, calling it a "just outcome."
Shkreli's lawyers did not immediately respond to a request for comment.
Shkreli is serving a seven-year prison sentence for securities fraud. He did not attend the trial held last month.
Vyera was founded in 2014 as Turing Pharmaceuticals, and acquired Daraprim from Impax Laboratories Inc in 2015.
Regulators accused Vyera of protecting its dominance of Daraprim by ensuring that generic drugmakers could not obtain samples for cheaper versions, and keeping potential rivals from buying a key ingredient.
The seven states joining the FTC case included California, Illinois, New York, North Carolina, Ohio, Pennsylvania and Virginia.
By David Randall NEW YORK (Reuters) -Bad news may once again be good news on Wall Street, as signs of slowing U.S. growth fan hopes that the Federal Reserve may not need to...
By Ann Saphir and Howard Schneider (Reuters) - Evidence U.S. inflation is cooling will not budge Federal Reserve policymakers from half-point interest rate hikes planned for...
WASHINGTON (Reuters) - The U.S. Federal Reserve is carrying $330 billion in unrealized losses on its holdings of U.S. Treasury and mortgage-backed securities as of the end of...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.